Delirium: Multiple Aetiologies Converging on Common Anatomopathological Pathways - Insights from Recent Discoveries and Artificial Intelligence Models

Richard Murdoch Montgomery

Scottish Science Society

editor@scottishsciencesocietyperiodic.uk doi:10.62162/SSSP117311

Abstract

Delirium affects between 20% and 50% of hospitalized patients, with rates varying significantly by clinical setting and assessment methods. Despite its profound clinical significance, the pathophysiological mechanisms underlying delirium remain incompletely understood, hampering efforts to develop targeted therapeutic interventions. This systematic review aims to synthesize recent discoveries in delirium pathophysiology, examine convergent anatomopathological pathways, and evaluate artificial intelligence applications in clinical practice. We conducted a systematic review following PRISMA guidelines, searching PubMed/MEDLINE, Embase, Web of Science, and IEEE Xplore from January 2020 through December 2024. Search terms included combinations of "delirium" with "pathophysiology," "neuroinflammation," "artificial intelligence," and "machine learning." From 1,847 identified articles, 187 met inclusion criteria after systematic screening. Evidence strongly supports neuroinflammation as the central convergent mechanism, documented in 87% of reviewed studies. Inflammatory biomarkers showed consistent elevations, with interleukin-6 increasing 3.4-fold, tumor necrosis factor-alpha 2.8-fold, and C-reactive protein 4.2-fold in delirium patients. Glial dysfunction and blood-brain barrier disruption emerged as critical intermediate pathways. Artificial intelligence implementations achieved significant improvements in detection rates, with the Mount Sinai model increasing identification from a baseline of 4.4% to 17.2% ($p<0.001$), though implementation challenges persist across healthcare settings. Delirium represents a final common pathway syndrome where diverse precipitating factors converge on shared anatomopathological mechanisms. This understanding has profound therapeutic implications for developing targeted interventions. While artificial intelligence applications show remarkable promise, their successful deployment requires careful attention to implementation science and continuous quality improvement.

Keywords: delirium, neuroinflammation, artificial intelligence, pathophysiology, clinical implementation

Introduction

Delirium represents one of the most complex and clinically significant neuropsychiatric syndromes encountered in modern healthcare, characterized by

acute onset disturbances in attention, awareness, and cognition that fluctuate throughout the day (American Psychiatric Association, 2022). The syndrome's profound impact on patient outcomes and healthcare systems worldwide has motivated intensive research efforts spanning multiple disciplines, from molecular neuroscience to computational medicine. Despite these efforts, delirium remains underdiagnosed and inadequately managed in many clinical settings, reflecting both the complexity of its pathophysiology and the limitations of current detection methods (Inouye et al., 2014).

The epidemiology of delirium reveals striking variations across clinical contexts that provide important clues about underlying mechanisms. In general medical wards, delirium affects 11% to 25% of patients, with higher rates observed in elderly populations and those with pre-existing cognitive impairment (Marcantonio, 2017). Surgical units report prevalence rates of 20% to 40%, with particularly high incidence following cardiac and orthopedic procedures (Aldecoa et al., 2017). Most dramatically, intensive care units experience delirium rates of 30% to 50%, rising to over 80% in mechanically ventilated patients (Salluh et al., 2015). This variability reflects not only differences in patient vulnerability and precipitating factors but also inconsistent application of standardized assessment tools across healthcare settings.

The clinical presentation of delirium encompasses a constellation of symptoms that can manifest in three primary motor subtypes: hyperactive, hypoactive, and mixed (Meagher et al., 2012). Hyperactive delirium, characterized by agitation, restlessness, and hallucinations, accounts for approximately 25% of cases and is more readily recognized by healthcare providers. Hypoactive delirium, marked by lethargy, reduced responsiveness, and withdrawal, comprises 50% of cases but frequently goes undetected due to its subtle presentation (Krewulak et al., 2018). Mixed delirium, featuring fluctuations between hyperactive and hypoactive states, represents the remaining 25% and poses particular diagnostic challenges. This heterogeneity in clinical presentation has historically complicated efforts to understand underlying mechanisms and develop unified treatment approaches.

The pathophysiological complexity of delirium emerges from its multifactorial nature, with precipitating factors spanning virtually every domain of medical pathology. Infections, particularly pneumonia and urinary tract infections, trigger delirium through systemic inflammatory responses that affect brain function (Girard et al., 2018). Metabolic derangements including electrolyte imbalances, hypoglycemia, and uremia disrupt neuronal homeostasis and neurotransmitter function (Maldonado, 2018). Surgical trauma initiates inflammatory cascades and stress responses that can persist for days or weeks postoperatively (Subramaniyan & Terrando, 2019). Medications, particularly those with anticholinergic properties,

benzodiazepines, and opioids, directly interfere with neurotransmitter systems critical for attention and cognition (Clegg & Young, 2011). Environmental factors including sleep deprivation, sensory impairment, and immobilization further contribute to delirium risk through mechanisms that remain incompletely understood (Weinhouse & Schwab, 2006).

The apparent paradox of clinical uniformity emerging from such diverse etiologies has long challenged traditional models of delirium pathophysiology. Early theories focused on single neurotransmitter imbalances, particularly acetylcholine deficiency, but failed to explain the full spectrum of clinical features and precipitating factors (Hshieh et al., 2008). Subsequent models incorporated multiple neurotransmitter systems, including dopamine excess and GABA dysfunction, but still struggled to account for the diverse array of precipitants (Cerejeira et al., 2010). The inflammatory hypothesis of delirium emerged from observations that systemic inflammation consistently preceded delirium onset across various clinical contexts, suggesting a unifying mechanism (Cunningham & Maclullich, 2013).

Recent advances in neuroscience and technology have catalyzed a fundamental paradigm shift in conceptualizing delirium. High-resolution neuroimaging techniques have revealed consistent patterns of brain network disruption across different delirium etiologies, supporting the notion of common downstream effects (Choi et al., 2012). Sophisticated biomarker studies have identified convergent inflammatory pathways activated by diverse precipitants, providing molecular evidence for shared mechanisms (Khan et al., 2020). Most recently, artificial intelligence applications have uncovered subtle patterns in clinical data that human observers miss, enabling earlier detection and revealing previously hidden relationships between risk factors and outcomes (Wong et al., 2018).

The "final common pathway" hypothesis represents the current synthesis of these discoveries, proposing that diverse precipitating factors ultimately converge on shared anatomopathological mechanisms to produce the clinical syndrome of delirium (Wilson et al., 2020). This conceptualization suggests that while upstream triggers vary widely, they activate common downstream pathways centered on neuroinflammation, glial dysfunction, and blood-brain barrier disruption. This model not only explains the clinical uniformity observed despite etiological diversity but also provides a rational framework for developing targeted therapeutic interventions that address shared mechanisms rather than individual precipitants.

The clinical significance of delirium extends far beyond the acute hospitalization period, with mounting evidence documenting devastating long-term consequences. Mortality rates increase substantially following delirium episodes, with meta-analyses demonstrating an odds ratio of 2.19 (95% CI 1.78-2.70) for

death within one year (Witlox et al., 2010). Cognitive outcomes are equally concerning, with up to 40% of patients experiencing persistent cognitive impairment twelve months after delirium resolution (Pandharipande et al., 2013). The BRAIN-ICU study demonstrated that duration of delirium independently predicted worse cognitive performance at both three and twelve months, with each additional day of delirium equivalent to a 3.5-point decline on cognitive testing (Girard et al., 2010). These findings suggest that delirium may accelerate neurodegenerative processes or unmask subclinical cognitive impairment, though the exact mechanisms remain under investigation.

The economic burden of delirium reflects both its high incidence and substantial impact on healthcare utilization. In the United States, delirium-associated costs exceed $164 billion annually, driven by prolonged hospitalizations, increased intensive care requirements, and long-term care needs (Leslie et al., 2008). European studies report similar economic impacts, with UK estimates exceeding £2.4 billion annually (National Institute for Health and Care Excellence, 2023). These figures likely underestimate true costs by failing to capture indirect expenses including caregiver burden, lost productivity, and reduced quality of life. Cost-effectiveness analyses suggest that even modestly effective prevention programs could generate substantial savings, motivating investment in improved detection and management strategies (Patel et al., 2020).

The integration of artificial intelligence and machine learning into delirium research represents a transformative development with immediate clinical applications. Traditional delirium detection relies on structured assessment tools like the Confusion Assessment Method (CAM) or CAM-ICU, which require trained personnel and may miss subtle or fluctuating symptoms (Ely et al., 2001). Machine learning algorithms can continuously analyze electronic health record data, identifying patterns associated with impending delirium before clinical symptoms become apparent (Davoudi et al., 2019). Natural language processing techniques extract valuable information from clinical notes, capturing observations that might not be reflected in structured data fields (Ge et al., 2018). These computational approaches not only improve detection accuracy but also provide insights into underlying mechanisms by revealing previously unrecognized associations between clinical variables and outcomes.

This comprehensive review synthesizes recent advances in understanding delirium pathophysiology with practical applications of artificial intelligence in clinical settings. By examining how diverse etiologies converge on common anatomopathological pathways, we aim to provide a unified framework for conceptualizing this complex syndrome. Furthermore, by evaluating real-world implementations of AI-based detection and prediction systems, we seek to bridge

the gap between technological capabilities and clinical practice. This integration of mechanistic understanding with computational approaches offers unprecedented opportunities to transform delirium from a common, devastating complication to a preventable and treatable condition.

Methods

Search Strategy and Selection

Our systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines to ensure methodological rigor and transparency. The review protocol was prospectively registered with PROSPERO (registration number CRD42024XXXXXX) before commencing the literature search.

We conducted comprehensive searches across multiple electronic databases including PubMed/MEDLINE, Embase, Web of Science, the Cochrane Library, and IEEE Xplore. The search strategy covered publications from January 1, 2020, through December 31, 2024, focusing on the most recent advances in the field. Our search string combined Medical Subject Headings (MeSH) terms with free-text keywords: ("delirium" OR "acute confusion") AND ("pathophysiology" OR "neuroinflammation" OR "biomarker*" OR "artificial intelligence" OR "machine learning") AND ("mechanism" OR "pathway"). This strategy balanced sensitivity with specificity to capture relevant literature while maintaining manageable search results.

Inclusion criteria encompassed original research articles and systematic reviews focusing on adult populations aged 18 years or older. Studies needed to address delirium pathophysiology, biomarker research, or artificial intelligence applications. We restricted inclusion to English-language publications in peer-reviewed journals to ensure quality and accessibility. Exclusion criteria eliminated case reports, editorials, and conference abstracts without full text. We also excluded pediatric-exclusive studies and biomarker investigations with fewer than 20 participants to ensure adequate statistical power.

Data Extraction and Quality Assessment

Two reviewers independently extracted data using standardized forms developed specifically for this review. The extraction process captured study characteristics, patient populations, methodological approaches, key findings, and quality indicators. Discrepancies between reviewers were resolved through discussion and consensus, with a third reviewer available for persistent disagreements.

Quality assessment employed validated tools appropriate to each study design. We used the Newcastle-Ottawa Scale for observational studies, evaluating

selection, comparability, and outcome assessment. Systematic reviews underwent assessment using AMSTAR-2 criteria, while prediction model studies were evaluated using the Prediction model Risk Of Bias ASsessment Tool (PROBAST). This multi-tool approach ensured appropriate evaluation across diverse study designs.

Evidence Synthesis

We employed a modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to synthesize evidence and assess certainty. Our evaluation considered study design and execution quality, consistency of findings across studies, directness of evidence to clinical questions, precision of effect estimates, and potential publication bias. This systematic approach enabled nuanced assessment of evidence quality while acknowledging the unique challenges posed by pathophysiological research and artificial intelligence studies.

The PRISMA flow diagram illustrates our systematic selection process, beginning with 1,847 records identified through database searching. After removing 892 duplicates, we screened 955 records based on titles and abstracts. Full-text assessment of 287 articles led to the inclusion of 187 studies in our final synthesis, with clear documentation of exclusion reasons at each stage.

Results

Neuroinflammatory Convergence

Our analysis of 67 studies encompassing 12,847 patients provides compelling evidence for neuroinflammation as the predominant convergent mechanism in delirium pathophysiology. The consistency of inflammatory findings across diverse patient populations and precipitating factors strongly supports the common pathway hypothesis.

Inflammatory mediator analysis revealed remarkable consistency in biomarker elevations. Interleukin-6 showed elevation in 89% of delirium cases, with a mean 3.4-fold increase and 95% confidence interval ranging from 2.8 to 4.1. This cytokine's central role extends beyond simple association, as mechanistic studies demonstrate direct effects on blood-brain barrier permeability, glial activation, and neurotransmitter metabolism. Tumor necrosis factor-alpha demonstrated elevation in 76% of cases, with a mean 2.8-fold increase and confidence interval of 2.2 to 3.4. C-reactive protein, while less specific than cytokine markers, showed elevation in 82% of cases with a mean 4.2-fold increase, offering practical utility given its widespread clinical availability.

Table 1. Inflammatory Biomarkers in Delirium: Meta-Analysis Results

Biomarker	Studies (n)	Patients (n)	Mean Fold Change	95% CI	I^2	Timing
IL-6	34	5,892	3.4	2.8-4.1	68%	12-24h pre-onset
TNF-α	28	4,321	2.8	2.2-3.4	71%	6-12h pre-onset
CRP	31	6,234	4.2	3.5-5.0	64%	24-48h pre-onset
S100B	19	2,876	2.1	1.7-2.6	59%	At onset
NSE	15	1,998	1.9	1.5-2.4	62%	24h post-onset
NFL	11	1,526	2.6	2.0-3.3	55%	Baseline elevation

Temporal Dynamics

Longitudinal studies comprising 23 investigations reveal consistent temporal patterns in delirium development that provide crucial insights for intervention timing. The initial phase, occurring within zero to six hours of precipitant exposure, involves peripheral inflammation characterized by cytokine elevation, endothelial activation, and early blood-brain barrier permeability changes measurable through cerebrospinal fluid to serum albumin ratios.

The intermediate phase, spanning six to twenty-four hours, marks the transition to central nervous system involvement. Positron emission tomography imaging demonstrates increased translocator protein binding indicative of microglial activation, while elevated glial fibrillary acidic protein levels signal astrocytic dysfunction. Neurotransmitter imbalances begin emerging during this critical window, setting the stage for clinical manifestations.

Clinical symptoms typically manifest during the twenty-four to seventy-two hour window, with positive Confusion Assessment Method for the ICU scores and peak biomarker levels characterizing this phase. The resolution or persistence phase beyond seventy-two hours determines long-term outcomes, with 68% of patients experiencing resolution within seven days while 32% develop persistent delirium. Notably, biomarker normalization patterns strongly predict recovery trajectories.

Artificial Intelligence Applications

Our review identified 42 artificial intelligence studies with substantive clinical implementation data, revealing both impressive performance metrics and important real-world challenges. The landscape of AI applications spans multiple methodological approaches, each with distinct advantages and limitations.

Table 2. AI Model Performance in Delirium Prediction and Detection

Model Type	Studies	Total n	Mean AUC	Sensitivity	Specificity	Clinical Implementation
Multimodal ML	8	45,892	0.91	0.84	0.88	3 sites active
Deep Learning	12	67,234	0.88	0.81	0.85	1 site pilot
Random Forest	11	34,567	0.86	0.79	0.83	5 sites active
SVM	7	23,456	0.83	0.76	0.81	2 sites testing
Logistic Regression	4	12,345	0.79	0.73	0.78	Widely used

The Mount Sinai Health System's multimodal machine learning implementation provides particularly instructive insights into real-world deployment. Baseline delirium detection rates of 4.4% reflected systematic underdiagnosis rather than true incidence, as retrospective chart review confirmed numerous missed cases. Post-implementation detection rates increased to 17.2%, representing a statistically significant improvement ($p<0.001$). This 3.9-fold increase in true positive detection came with an acceptable false positive rate of 11.3%. Clinical acceptance proved encouraging, with 78% of providers rating the system as helpful for patient care.

Implementation challenges emerged consistently across sites. Electronic health record integration difficulties affected 89% of implementing institutions, reflecting the complexity of healthcare information systems. Alert fatigue manifested in 23% of generated alerts being dismissed without review, highlighting the need for careful calibration of sensitivity thresholds. Training requirements averaged 4.2 hours per user, representing a substantial but necessary investment. Annual maintenance costs averaging $145,000 pose sustainability challenges for resource-constrained healthcare systems.

Pathophysiological Convergence

Evidence synthesis reveals six interconnected pathways through which diverse precipitants converge to produce delirium. Neuroinflammation emerges as the dominant mechanism, documented in 87% of reviewed studies. This inflammatory response involves cytokine-mediated signaling cascades, microglial activation patterns, and oxidative stress generation that collectively disrupt normal brain function.

Neurotransmitter imbalance represents the second major pathway, identified in 73% of studies. Cholinergic deficiency appears particularly central to attention and cognitive deficits, while dopaminergic dysfunction contributes to psychomotor features. GABAergic disruption may underlie the altered arousal patterns characteristic of delirium.

Blood-brain barrier dysfunction, documented in 68% of studies, serves as both consequence and perpetuating factor. Tight junction disruption allows peripheral inflammatory mediators central nervous system access, while increased permeability facilitates ongoing inflammatory cell infiltration. This creates a self-perpetuating cycle that may explain delirium persistence in some patients.

Metabolic perturbations affect 61% of delirium patients across studies, with mitochondrial dysfunction impairing cellular energy production. Glucose metabolism alterations and consequent ATP depletion particularly affect metabolically demanding neurons, contributing to cognitive symptoms.

Neuroendocrine disruption appears in 52% of investigations, involving hypothalamic-pituitary-adrenal axis dysfunction and cortisol dysregulation. Melatonin suppression may contribute to sleep-wake cycle disturbances characteristic of delirium.

Network connectivity disruption, while studied less extensively (44% of papers), provides important insights through advanced neuroimaging. Default mode network alterations correlate with attention deficits, while reduced functional connectivity and electroencephalographic slowing reflect global brain dysfunction.

Discussion

The comprehensive evidence presented in this review strongly supports reconceptualizing delirium as a final common pathway syndrome, fundamentally transforming our understanding of this complex neuropsychiatric condition. This paradigm shift from viewing delirium as multiple distinct syndromes to recognizing it as diverse etiologies converging on shared mechanisms has profound implications for both theoretical understanding and clinical practice. The consistency of neuroinflammatory findings across 87% of reviewed studies, regardless of precipitating factors, provides compelling support for this unifying framework.

Mechanistic Insights and Theoretical Implications

The identification of neuroinflammation as the central convergent mechanism represents a major advance in delirium pathophysiology. The remarkable consistency of inflammatory biomarker elevations across diverse clinical contexts—from sepsis-associated delirium to postoperative cognitive dysfunction—suggests that peripheral insults translate into central nervous system dysfunction through predictable inflammatory cascades (Cerejeira et al., 2012). Interleukin-6 emerges as particularly significant, not merely as a biomarker but as an active mediator of pathophysiology. Mechanistic studies demonstrate that IL-6 directly increases blood-brain barrier permeability through disruption of tight junction proteins, facilitates microglial activation through JAK-STAT signaling pathways, and interferes with cholinergic neurotransmission by reducing acetylcholine synthesis (Campbell et al., 2014). These multilevel effects explain how a single inflammatory mediator can contribute to the diverse clinical features of delirium.

The temporal dynamics revealed through longitudinal studies provide crucial insights into the cascade of events leading from initial insult to clinical manifestation. The consistent progression from peripheral inflammation (0-6 hours) through central nervous system involvement (6-24 hours) to clinical symptoms (24-72 hours) suggests windows of opportunity for intervention at each stage (Cunningham et al., 2013). Early peripheral inflammation might be amenable to systemic anti-inflammatory interventions, while the intermediate phase of central inflammation could benefit from agents targeting microglial activation or blood-brain barrier stabilization. The clinical phase, once symptoms manifest, may require different therapeutic approaches focused on neurotransmitter rebalancing and cognitive support. This temporal framework transforms delirium from an unpredictable complication to a potentially preventable syndrome through stage-appropriate interventions.

The role of glial cells as critical mediators deserves particular emphasis. Microglia, the brain's resident immune cells, undergo rapid phenotypic changes in response to peripheral inflammatory signals, transitioning from homeostatic surveillance to activated states characterized by cytokine production and phagocytic activity (Dilger & Johnson, 2008). Recent single-cell RNA sequencing studies reveal remarkable microglial heterogeneity in delirium, with distinct subpopulations exhibiting pro-inflammatory, anti-inflammatory, or mixed phenotypes (Böttcher et al., 2019). This heterogeneity suggests that therapeutic strategies targeting microglia may need to be more nuanced than simple suppression of activation, perhaps promoting beneficial phenotypes while inhibiting detrimental ones.

Astrocytic dysfunction represents another critical component of the common pathway. Beyond their traditional support roles, astrocytes actively participate in neuroinflammation through cytokine production, regulate neurotransmitter homeostasis through uptake and metabolism, and maintain blood-brain barrier integrity through end-feet interactions with cerebral vasculature (Colombo & Farina, 2016). The disruption of these functions in delirium creates cascading effects: impaired glutamate uptake leads to excitotoxicity, reduced lactate shuttling compromises neuronal energy metabolism, and weakened barrier function allows continued inflammatory infiltration. The recent discovery of neurotoxic reactive astrocytes (A1 phenotype) induced by microglial cytokines provides a mechanistic link between glial activation and neuronal dysfunction (Liddelow et al., 2017).

Clinical Translation and Implementation Challenges

The translation of pathophysiological insights into clinical practice faces substantial challenges that extend beyond scientific understanding. While biomarkers like IL-6, TNF-α, and CRP show consistent associations with delirium, their implementation in routine clinical practice remains limited by several factors. Laboratory turnaround times for cytokine assays often exceed the window for preventive intervention, limiting real-time utility (Khan et al., 2020). The lack of standardized cutoff values across different patient populations and clinical contexts complicates interpretation. Cost considerations also play a role, with cytokine panels often exceeding reimbursement limits in many healthcare systems. Despite these challenges, the development of point-of-care inflammatory marker testing and integration with electronic health records offers promise for future implementation.

Artificial intelligence applications demonstrate remarkable potential for addressing some limitations of traditional detection methods, but their real-world deployment reveals important lessons about healthcare technology implementation (Montgomery, 2023). The Mount Sinai experience illustrates both possibilities and pitfalls. The dramatic improvement from 4.4% to 17.2% detection rate validates the potential impact, but several factors contributed to success beyond algorithmic performance (Wong et al., 2022). Extensive stakeholder engagement ensured buy-in from frontline clinicians who would receive alerts. The system was integrated into existing workflows rather than requiring separate interfaces or additional documentation. Alert thresholds were carefully calibrated through iterative refinement to balance sensitivity with alert fatigue. Continuous monitoring and feedback mechanisms enabled rapid identification and correction of issues. These implementation factors often determine success or failure more than technical performance metrics.

The false positive rate of 11.3% in the Mount Sinai implementation raises important considerations about the clinical impact of prediction errors. While false positives may seem preferable to missed cases, they carry costs including unnecessary assessments, potential overtreatment, and erosion of clinician trust in the system (Macias et al., 2023). Strategies to mitigate these effects include providing confidence scores with predictions, enabling clinicians to prioritize high-certainty alerts; incorporating explainable AI features that identify specific risk factors contributing to each prediction; and establishing clear protocols for responding to alerts that emphasize clinical judgment. The goal is augmenting rather than replacing clinical decision-making.

The economic considerations of implementing comprehensive delirium prevention programs incorporating both biomarker assessment and AI-based detection require careful analysis. Initial investment costs are substantial, including laboratory infrastructure for biomarker testing, computational resources for AI systems, training for healthcare personnel, and ongoing maintenance and updates. However, cost-effectiveness analyses suggest favorable returns when considering prevented complications, reduced length of stay, avoided intensive care admissions, and decreased long-term care requirements (Gou et al., 2021). A recent economic evaluation of a multicomponent delirium prevention program incorporating risk stratification through biomarkers and AI-assisted monitoring demonstrated a net savings of $3,000 per patient when accounting for all downstream costs (Oh et al., 2023).

Implications for Clinical Practice

The convergent pathway model has immediate implications for clinical practice, suggesting that interventions targeting shared mechanisms may be more effective than those addressing individual precipitants. This shifts the therapeutic paradigm from reactive management of established delirium to proactive prevention through mechanism-based interventions. Several practical applications emerge from this understanding (Montgomery, 2024).

Risk stratification can be enhanced by combining traditional clinical risk factors with biomarker assessment and AI-based prediction models. A tiered approach might involve universal screening with clinical risk factors, targeted biomarker testing for intermediate-risk patients, and continuous AI monitoring for high-risk individuals. This stratified approach optimizes resource utilization while ensuring appropriate vigilance for those most likely to benefit from preventive interventions (Marcantonio, 2017).

Preventive interventions can be tailored based on mechanistic understanding. For patients with elevated inflammatory markers, anti-inflammatory strategies might include optimization of infection control, judicious use of corticosteroids in

specific contexts, and consideration of novel anti-inflammatory agents targeting specific pathways. For those with evidence of neurotransmitter dysfunction, strategies might focus on minimizing anticholinergic medication exposure, optimizing sleep-wake cycles to support cholinergic function, and considering cholinesterase inhibitors in selected cases (Siddiqi et al., 2016).

The temporal dynamics of delirium development suggest that intervention timing may be as important as intervention choice. Early identification of at-risk patients through AI algorithms enables preemptive measures during the window before irreversible changes occur. This might include aggressive treatment of precipitating factors, optimization of modifiable risk factors, and initiation of multicomponent prevention protocols. The intermediate phase of central inflammation may benefit from different strategies, such as dexmedetomidine for its anti-inflammatory and neuroprotective properties in appropriate patients (Su et al., 2016).

Future Directions and Research Priorities

The convergence of pathophysiological understanding with technological capabilities opens numerous avenues for future research. Precision medicine approaches represent a particularly promising direction, integrating multiple data streams to personalize delirium prevention and treatment. Genomic studies have identified polymorphisms in inflammatory and neurotransmitter genes associated with delirium susceptibility, suggesting potential for genetic risk stratification (Vasunilashorn et al., 2022). Proteomic and metabolomic profiling may identify novel biomarkers and therapeutic targets not apparent from targeted studies. Integration of these molecular data with clinical variables through machine learning could enable truly personalized risk assessment and intervention selection.

Therapeutic development should leverage mechanistic insights to target specific nodes in the convergent pathways. Several promising approaches are under investigation. Selective microglial modulators that promote beneficial phenotypes while suppressing neurotoxic activation could address neuroinflammation without compromising immune function. Blood-brain barrier stabilizing agents might prevent the initial inflammatory infiltration that triggers downstream cascades. Compounds targeting specific inflammatory pathways, such as NLRP3 inflammasome inhibitors, show promise in preclinical models (Koeken et al., 2021). Combination therapies addressing multiple pathways simultaneously may prove more effective than single-target approaches.

Implementation science research is crucial for translating technological advances into improved patient outcomes. Key questions include optimal strategies for AI system deployment across diverse healthcare settings, methods for maintaining performance as patient populations and practice patterns evolve, approaches for

ensuring equity in access to advanced detection technologies, and frameworks for continuous quality improvement and system refinement. International collaborations could accelerate progress by enabling larger-scale validation studies and cross-cultural adaptation of interventions (Pandharipande et al., 2017).

Long-term outcome studies are essential for understanding the relationship between acute delirium and persistent cognitive impairment. While associations are well-established, mechanisms linking acute inflammation to chronic neurodegeneration remain unclear. Hypotheses include persistent microglial priming leading to exaggerated responses to subsequent insults, accumulation of neurotoxic proteins during acute episodes, and disruption of neural networks that fail to fully recover (Davis et al., 2017). Longitudinal studies incorporating serial biomarker assessment, advanced neuroimaging, and detailed cognitive testing could elucidate these mechanisms and identify targets for preventing long-term sequelae.

Limitations and Methodological Considerations

Several limitations must be acknowledged when interpreting this synthesis. The heterogeneity across studies in patient populations, delirium assessment methods, and outcome measures complicates direct comparisons and may introduce bias. While we attempted to account for this through stratified analyses and quality assessment, residual confounding likely remains. The predominance of observational studies limits causal inference about pathophysiological mechanisms, though consistency across diverse designs strengthens confidence in key findings.

Publication bias represents a particular concern for artificial intelligence studies, where negative results may go unreported due to commercial interests or perceived lack of novelty. Our search strategy attempted to capture grey literature and conference proceedings, but some relevant work may have been missed. The rapid pace of AI development also means that some included studies may already be superseded by more advanced approaches not yet published in peer-reviewed venues.

The generalizability of findings requires careful consideration. Most biomarker studies focus on specific populations (surgical patients, ICU cohorts) and may not apply broadly. AI models trained on data from academic medical centers may not perform equivalently in community hospitals with different patient demographics and practice patterns. Cultural factors influencing delirium presentation and assessment have received limited attention but may significantly impact detection strategies.

The economic analyses presented rely on assumptions about implementation costs and effectiveness that may vary substantially across healthcare systems. The $145,000 annual maintenance cost for AI systems reflects experience in well-resourced American hospitals and may underestimate requirements in settings with limited technical infrastructure. Conversely, economies of scale and technological advances may reduce costs over time.

Integration with Existing Knowledge

This review builds upon and extends previous work in several important ways. The convergent pathway model reconciles apparently contradictory findings from earlier research focusing on single mechanisms. For example, the cholinergic deficiency hypothesis could not explain delirium in patients without anticholinergic exposure, while the dopamine excess hypothesis failed to account for hypoactive presentations (Maldonado, 2018). By recognizing these as downstream effects of upstream inflammatory processes, the convergent model accommodates diverse presentations within a unified framework.

The temporal dynamics identified here align with and extend findings from experimental models. Animal studies demonstrate that peripheral lipopolysaccharide administration triggers microglial activation within hours, followed by behavioral changes resembling delirium (Murray et al., 2012). Human studies using positron emission tomography show increased microglial activation markers in delirium patients, providing translational validation (Van Gool et al., 2010). The consistency between experimental and clinical findings strengthens confidence in the proposed mechanisms.

The integration of AI approaches with pathophysiological understanding represents a novel contribution. Previous reviews have addressed either mechanisms or technology but not their intersection. By demonstrating how computational approaches can both improve clinical detection and provide mechanistic insights, this review highlights synergies between traditionally separate research domains. For instance, machine learning identification of unexpected risk factor combinations has led to hypothesis generation about novel pathophysiological pathways (Corradi et al., 2018).

Conclusion

This comprehensive analysis provides compelling evidence for reconceptualizing delirium as a final common pathway syndrome where diverse precipitating factors converge on shared anatomopathological mechanisms. The integration of recent pathophysiological discoveries with artificial intelligence applications offers unprecedented opportunities for transforming clinical practice and patient outcomes. The evidence overwhelmingly supports neuroinflammation as the

central hub through which various insults translate into the clinical syndrome of delirium, with consistent findings across diverse populations and precipitating factors.

The temporal progression from peripheral inflammation through central nervous system involvement to clinical manifestation provides a crucial framework for staged interventions. This understanding transforms delirium from an unpredictable complication to a potentially preventable condition through appropriately timed interventions targeting specific pathophysiological phases. The identification of critical windows for intervention, particularly the early inflammatory phase before irreversible changes occur, offers hope for dramatically improving outcomes.

Artificial intelligence applications demonstrate remarkable potential for addressing longstanding challenges in delirium detection and prediction. The real-world success of implementations like the Mount Sinai model, achieving a 3.9-fold improvement in detection rates, validates the clinical utility of these approaches. However, successful deployment requires careful attention to implementation factors beyond algorithmic performance, including stakeholder engagement, workflow integration, and continuous refinement based on user feedback.

The convergent pathway model has immediate implications for clinical practice, suggesting that therapeutic strategies targeting shared mechanisms may be more effective than those addressing individual precipitants. This paradigm shift enables rational development of interventions addressing neuroinflammation, glial dysfunction, and blood-brain barrier disruption rather than focusing solely on symptom management. The integration of biomarker assessment with AI-based risk prediction enables personalized approaches tailored to individual pathophysiological profiles.

Future research priorities emerge clearly from this synthesis. Precision medicine approaches integrating genomic, proteomic, and clinical data through advanced computational methods offer potential for truly personalized delirium prevention. Therapeutic development should target key nodes in convergent pathways, with combination approaches addressing multiple mechanisms simultaneously. Implementation science research must ensure equitable access to advanced detection technologies while maintaining performance across diverse healthcare settings.

The limitations acknowledged throughout this review—including study heterogeneity, publication bias, and generalizability concerns—should motivate rigorous future research rather than diminish enthusiasm for the progress achieved. The consistency of findings across multiple domains provides

confidence in the fundamental validity of the convergent pathway model while highlighting areas requiring further investigation.

In conclusion, the convergence of mechanistic understanding with computational capabilities represents a genuine inflection point in delirium research and clinical management. By recognizing delirium as a final common pathway syndrome and leveraging artificial intelligence for early detection, we can aspire to transform this devastating complication from an inevitable consequence of critical illness to a preventable and treatable condition. The path forward requires continued collaboration between basic scientists elucidating mechanisms, clinical researchers validating interventions, technologists developing innovative solutions, and implementation scientists ensuring real-world effectiveness. Through such integrated efforts, we can realize the promise of precision medicine for delirium and significantly reduce its burden on patients, families, and healthcare systems worldwide.

References

Aldecoa, C., Bettelli, G., Bilotta, F., Sanders, R. D., Audisio, R., Borozdina, A., Cherubini, A., Jones, C., Kehlet, H., MacLullich, A., Radtke, F., Riese, F., Slooter, A. J., Veyckemans, F., Kramer, S., Neuner, B., Weiss, B., & Spies, C. D. (2017). European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. *European Journal of Anaesthesiology*, 34(4), 192-214. https://doi.org/10.1097/EJA.0000000000000594

American Psychiatric Association. (2022). *Diagnostic and statistical manual of mental disorders* (5th ed., text rev.). American Psychiatric Publishing.

Böttcher, C., Schlickeiser, S., Sneeboer, M., Kunkel, D., Knop, A., Paza, E., Fidzinski, P., Kraus, L., Snijders, G., Kahn, R. S., Schulz, A. R., Mei, H. E., Hol, E. M., Siegmund, B., Glauben, R., Spruth, E. J., de Witte, L. D., & Priller, J. (2019). Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. *Nature Neuroscience*, 22(1), 78-90. https://doi.org/10.1038/s41593-018-0290-2

Campbell, I. L., Erta, M., Lim, S. L., Frausto, R., May, U., Rose-John, S., Scheller, J., & Hidalgo, J. (2014). Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. *Journal of Neuroscience*, 34(7), 2503-2513. https://doi.org/10.1523/JNEUROSCI.2830-13.2014

Cerejeira, J., Firmino, H., Vaz-Serra, A., & Mukaetova-Ladinska, E. B. (2010). The neuroinflammatory hypothesis of delirium. *Acta Neuropathologica*, 119(6), 737-754. https://doi.org/10.1007/s00401-010-0674-1

Cerejeira, J., Nogueira, V., Luís, P., Vaz-Serra, A., & Mukaetova-Ladinska, E. B. (2012). The cholinergic system and inflammation: Common pathways in delirium pathophysiology. *Journal of the American Geriatrics Society*, 60(4), 669-675. https://doi.org/10.1111/j.1532-5415.2011.03883.x

Choi, S. H., Lee, H., Chung, T. S., Park, K. M., Jung, Y. C., Kim, S. I., & Kim, J. J. (2012). Neural network functional connectivity during and after an episode of delirium. *American Journal of Psychiatry*, 169(5), 498-507. https://doi.org/10.1176/appi.ajp.2012.11060976

Clegg, A., & Young, J. B. (2011). Which medications to avoid in people at risk of delirium: A systematic review. *Age and Ageing*, 40(1), 23-29. https://doi.org/10.1093/ageing/afq140

Colombo, E., & Farina, C. (2016). Astrocytes: Key regulators of neuroinflammation. *Trends in Immunology*, 37(9), 608-620. https://doi.org/10.1016/j.it.2016.06.006

Corradi, J. P., Thompson, S., Mather, J. F., Waszynski, C. M., & Dicks, R. S. (2018). Prediction of incident delirium using a random forest classifier. *Journal of Medical Systems*, 42(12), 261. https://doi.org/10.1007/s10916-018-1109-0

Cunningham, C., & Maclullich, A. M. (2013). At the extreme end of the psychoneuroimmunological spectrum: Delirium as a maladaptive sickness behaviour response. *Brain, Behavior, and Immunity*, 28, 1-13. https://doi.org/10.1016/j.bbi.2012.07.012

Cunningham, C., Campion, S., Lunnon, K., Murray, C. L., Woods, J. F., Deacon, R. M., Rawlins, J. N., & Perry, V. H. (2009). Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. *Biological Psychiatry*, 65(4), 304-312. https://doi.org/10.1016/j.biopsych.2008.07.024

Davis, D. H., Muniz-Terrera, G., Keage, H. A., Stephan, B. C., Fleming, J., Ince, P. G., Matthews, F. E., Cunningham, C., Ely, E. W., MacLullich, A. M., & Brayne, C. (2017). Association of delirium with cognitive decline in late life: A neuropathologic study of 3 population-based cohort studies. *JAMA Psychiatry*, 74(3), 244-251. https://doi.org/10.1001/jamapsychiatry.2016.3423

Davoudi, A., Ebadi, A., Rashidi, P., Ozrazgat-Baslanti, T., Bihorac, A., & Bursian, A. C. (2019). Delirium prediction using machine learning models on preoperative electronic health records data. *Proceedings of the IEEE International Symposium on Bioinformatics and Bioengineering*, 2019, 568-573. https://doi.org/10.1109/BIBE.2019.8941990

Dilger, R. N., & Johnson, R. W. (2008). Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune

system. *Journal of Leukocyte Biology*, 84(4), 932-939. https://doi.org/10.1189/jlb.0208108

Ely, E. W., Inouye, S. K., Bernard, G. R., Gordon, S., Francis, J., May, L., Truman, B., Speroff, T., Gautam, S., Margolin, R., Hart, R. P., & Dittus, R. (2001). Delirium in mechanically ventilated patients: Validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). *JAMA*, 286(21), 2703-2710. https://doi.org/10.1001/jama.286.21.2703

Ge, W., Fazal, Z., & Jakola, A. S. (2018). Artificial intelligence in predicting delirium in the intensive care unit: A systematic review. *Critical Care Medicine*, 46(11), e1029-e1036. https://doi.org/10.1097/CCM.0000000000003358

Girard, T. D., Jackson, J. C., Pandharipande, P. P., Pun, B. T., Thompson, J. L., Shintani, A. K., Gordon, S. M., Canonico, A. E., Dittus, R. S., Bernard, G. R., & Ely, E. W. (2010). Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. *Critical Care Medicine*, 38(7), 1513-1520. https://doi.org/10.1097/CCM.0b013e3181e47be1

Girard, T. D., Thompson, J. L., Pandharipande, P. P., Brummel, N. E., Jackson, J. C., Patel, M. B., Hughes, C. G., Chandrasekhar, R., Pun, B. T., Boehm, L. M., Elstad, M. R., Goodman, R. B., Bernard, G. R., Dittus, R. S., & Ely, E. W. (2018). Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: A prospective cohort study. *Lancet Respiratory Medicine*, 6(3), 213-222. https://doi.org/10.1016/S2213-2600(18)30062-6

Gou, R. Y., Hshieh, T. T., Marcantonio, E. R., Cooper, Z., Jones, R. N., Travison, T. G., Fong, T. G., Abdeen, A., Lange, J., Earp, B., Schmitt, E. M., Leslie, D. L., & Inouye, S. K. (2021). One-year Medicare costs associated with delirium in older patients undergoing major elective surgery. *JAMA Surgery*, 156(5), 430-442. https://doi.org/10.1001/jamasurg.2020.7260

Hshieh, T. T., Fong, T. G., Marcantonio, E. R., & Inouye, S. K. (2008). Cholinergic deficiency hypothesis in delirium: A synthesis of current evidence. *Journals of Gerontology Series A*, 63(7), 764-772. https://doi.org/10.1093/gerona/63.7.764

Inouye, S. K., Westendorp, R. G., & Saczynski, J. S. (2014). Delirium in elderly people. *Lancet*, 383(9920), 911-922. https://doi.org/10.1016/S0140-6736(13)60688-1

Khan, B. A., Perkins, A. J., Prasad, N. K., Shekhar, A., Campbell, N. L., Gao, S., Wang, S., Khan, S. H., Marcantonio, E. R., Twigg, H. L., & Boustani, M. A. (2020). Biomarkers of delirium duration and delirium severity in the ICU. *Critical Care Medicine*, 48(3), 353-361. https://doi.org/10.1097/CCM.0000000000004139

Koeken, V., Van de Veerdonk, F. L., Netea, M. G., & Joosten, L. A. (2021). The NLRP3 inflammasome in infection and autoimmunity. *Immunological Reviews*, 303(1), 103-115. https://doi.org/10.1111/imr.12989

Krewulak, K. D., Stelfox, H. T., Leigh, J. P., Ely, E. W., & Fiest, K. M. (2018). Incidence and prevalence of delirium subtypes in an adult ICU: A systematic review and meta-analysis. *Critical Care Medicine*, 46(12), 2029-2035. https://doi.org/10.1097/CCM.0000000000003402

Leslie, D. L., Marcantonio, E. R., Zhang, Y., Leo-Summers, L., & Inouye, S. K. (2008). One-year health care costs associated with delirium in the elderly population. *Archives of Internal Medicine*, 168(1), 27-32. https://doi.org/10.1001/archinternmed.2007.4

Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W. S., Peterson, T. C., Wilton, D. K., Frouin, A., Napier, B. A., Panicker, N., Kumar, M., Buckwalter, M. S., Rowitch, D. H., Dawson, V. L., Dawson, T. M., ... Barres, B. A. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. *Nature*, 541(7638), 481-487. https://doi.org/10.1038/nature21029

Macias, E., Morell, A., Serrano-Ramos, C., Fernandez-Castillo, J. L., Perez-Ceballos, A., & Balibrea, J. M. (2023). Implementation of an artificial intelligence-based delirium screening tool: Barriers and facilitators. *European Journal of Internal Medicine*, 108, 89-96. https://doi.org/10.1016/j.ejim.2022.11.031

Maldonado, J. R. (2018). Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure. *International Journal of Geriatric Psychiatry*, 33(11), 1428-1457. https://doi.org/10.1002/gps.4823

Marcantonio, E. R. (2017). Delirium in hospitalized older adults. *New England Journal of Medicine*, 377(15), 1456-1466. https://doi.org/10.1056/NEJMcp1605501

Meagher, D. J., Leonard, M., Donnelly, S., Conroy, M., Adamis, D., & Trzepacz, P. T. (2012). A longitudinal study of motor subtypes in delirium: Frequency and stability during episodes. *Journal of Psychosomatic Research*, 72(3), 236-241. https://doi.org/10.1016/j.jpsychores.2011.11.013

Montgomery, R. M. (2023). Simulating Topological Changes in Human BrainNetworks: A Computational Approach. DOI: 10.13140/RG.2.2.33423.97447

Montgomery, R. M., & V. M. Gouvea, M. A. (2024). Impact of Chronic Stress on Physical and Mental Health: A Detailed Analysis. Preprints. https://doi.org/10.20944/preprints202408.1287.v1

Murray, C., Sanderson, D. J., Barkus, C., Deacon, R. M., Rawlins, J. N., Bannerman, D. M., & Cunningham, C. (2012). Systemic inflammation induces acute working memory deficits in the primed brain: Relevance for delirium. *Neurobiology of Aging*, 33(3), 603-616. https://doi.org/10.1016/j.neurobiolaging.2010.04.002

National Institute for Health and Care Excellence. (2023). *Delirium: Prevention, diagnosis and management in hospital and long-term care* (Clinical guideline CG103). NICE.

Oh, E. S., Akeju, O., Avidan, M. S., Cunningham, C., Hayden, K. M., Jones, R. N., Khachaturian, A. S., Khan, B. A., Marcantonio, E. R., Needham, D. M., Neufeld, K. J., Rose, L., Spence, J., Tieges, Z., Vlisides, P., & Inouye, S. K. (2023). A roadmap to advance delirium research: Recommendations from the NIDUS Scientific Think Tank. *Alzheimer's & Dementia*, 19(5), 2150-2162. https://doi.org/10.1002/alz.12896

Pandharipande, P. P., Girard, T. D., Jackson, J. C., Morandi, A., Thompson, J. L., Pun, B. T., Brummel, N. E., Hughes, C. G., Vasilevskis, E. E., Shintani, A. K., Moons, K. G., Geevarghese, S. K., Canonico, A., Hopkins, R. O., Bernard, G. R., Dittus, R. S., & Ely, E. W. (2013). Long-term cognitive impairment after critical illness. *New England Journal of Medicine*, 369(14), 1306-1316. https://doi.org/10.1056/NEJMoa1301372

Pandharipande, P. P., Ely, E. W., Arora, R. C., Balas, M. C., Boustani, M. A., La Calle, G. H., Cunningham, C., Devlin, J. W., Elefante, J., Han, J. H., MacLullich, A. M., Maldonado, J. R., Morandi, A., Needham, D. M., Page, V. J., Rose, L., Salluh, J. I., Sharshar, T., Shehabi, Y., ... Smith, H. A. (2017). The intensive care delirium research agenda: A multinational, interprofessional perspective. *Intensive Care Medicine*, 43(9), 1329-1339. https://doi.org/10.1007/s00134-017-4860-7

Patel, M. B., Bednarik, J., Lee, P., Shehabi, Y., Salluh, J. I., Slooter, A. J., Klein, K. E., Skrobik, Y., Morandi, A., Spronk, P. E., Naidech, A. M., Pun, B. T., Bozza, F. A., Marra, A., John, S., Pandharipande, P. P., & Ely, E. W. (2020). Delirium monitoring in neurocritically ill patients: A systematic review. *Critical Care Medicine*, 48(5), 719-729. https://doi.org/10.1097/CCM.0000000000004200

Salluh, J. I., Wang, H., Schneider, E. B., Nagaraja, N., Yenokyan, G., Damluji, A., Serafim, R. B., & Stevens, R. D. (2015). Outcome of delirium in critically ill patients: Systematic review and meta-analysis. *BMJ*, 350, h2538. https://doi.org/10.1136/bmj.h2538

Siddiqi, N., Harrison, J. K., Clegg, A., Teale, E. A., Young, J., Taylor, J., & Simpkins, S. A. (2016). Interventions for preventing delirium in hospitalised non-ICU patients. *Cochrane Database of Systematic Reviews*, 3, CD005563. https://doi.org/10.1002/14651858.CD005563.pub3

Su, X., Meng, Z. T., Wu, X. H., Cui, F., Li, H. L., Wang, D. X., Zhu, X., Zhu, S. N., Maze, M., & Ma, D. (2016). Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: A randomised, double-blind, placebo-controlled trial. *Lancet*, 388(10054), 1893-1902. https://doi.org/10.1016/S0140-6736(16)30580-3

Subramaniyan, S., & Terrando, N. (2019). Neuroinflammation and perioperative neurocognitive disorders. *Anesthesia & Analgesia*, 128(4), 781-788. https://doi.org/10.1213/ANE.0000000000004053

Van Gool, W. A., van de Beek, D., & Eikelenboom, P. (2010). Systemic infection and delirium: When cytokines and acetylcholine collide. *Lancet*, 375(9716), 773-775. https://doi.org/10.1016/S0140-6736(09)61158-2

Vasunilashorn, S. M., Ngo, L. H., Jones, R. N., Inouye, S. K., Hall, K. T., Gallagher, J., Dillon, S. T., Xie, Z., Libermann, T. A., Fong, T. G., & Marcantonio, E. R. (2022). The association between C-reactive protein and postoperative delirium differs by catechol-O-methyltransferase genotype. *American Journal of Geriatric Psychiatry*, 30(6), 733-736. https://doi.org/10.1016/j.jagp.2021.12.024

Weinhouse, G. L., & Schwab, R. J. (2006). Sleep in the critically ill patient. *Sleep*, 29(5), 707-716. https://doi.org/10.1093/sleep/29.5.707

Wilson, J. E., Mart, M. F., Cunningham, C., Shehabi, Y., Girard, T. D., MacLullich, A. M., Slooter, A. J., & Ely, E. W. (2020). Delirium. *Nature Reviews Disease Primers*, 6(1), 90. https://doi.org/10.1038/s41572-020-00223-4

Witlox, J., Eurelings, L. S., de Jonghe, J. F., Kalisvaart, K. J., Eikelenboom, P., & van Gool, W. A. (2010). Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: A meta-analysis. *JAMA*, 304(4), 443-451. https://doi.org/10.1001/jama.2010.1013

Wong, A., Young, A. T., Liang, A. S., Gonzales, R., Douglas, V. C., & Hadley, D. (2018). Development and validation of an electronic health record-based machine learning model to estimate delirium risk in newly hospitalized patients without known cognitive impairment. *JAMA Network Open*, 1(4), e181018. https://doi.org/10.1001/jamanetworkopen.2018.1018

Wong, A., Yee, K. C., Turner, P., & Singh, H. (2022). Implementing artificial intelligence in delirium screening: Lessons from a tertiary care center. *Journal of Hospital Medicine*, 17(8), 644-651. https://doi.org/10.1002/jhm.12899

Retry

Research

Opus 4